152 related articles for article (PubMed ID: 12183901)
1. [Therapeutic monitoring of cyclosporine A].
Komzáková I; Safarcík K; Brozmanová H; Grundmann M
Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
3. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
[TBL] [Abstract][Full Text] [Related]
4. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
Halacová M; Jedlicková B; Průsa R
Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
Kahan BD
Transplant Proc; 2004 Mar; 36(2 Suppl):378S-391S. PubMed ID: 15041372
[TBL] [Abstract][Full Text] [Related]
6. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
7. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of cyclosporine.
Midtvedt K
Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
[TBL] [Abstract][Full Text] [Related]
9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
10. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
Glanville AR; Morton JM; Aboyoun CL; Plit ML; Malouf MA
J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
[TBL] [Abstract][Full Text] [Related]
15. [Problems associated with the use and monitoring of cyclosporin. Experience at a Clinical Pharmacology Service].
Loffreda A; Contaldi C; Santis DD; Marabese I; Chiaiese C; Formato P; Motola G; Russo F; D'Alessio O; Lampa E; Rossi F
Minerva Med; 1997 Dec; 88(12):543-9. PubMed ID: 9540786
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic monitoring and outcomes of cyclosporine.
Pollard SG
Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry-based pharmacodynamic monitoring after organ transplantation.
Dieterlen MT; Eberhardt K; Tarnok A; Bittner HB; Barten MJ
Methods Cell Biol; 2011; 103():267-84. PubMed ID: 21722807
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic monitoring of cyclosporine.
Woo J
Ann Clin Lab Sci; 1994; 24(1):60-8. PubMed ID: 8147569
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
